开云app官网登录入口网页版-官方正版

#CAF#

15篇内容 | 981人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2007562, encodeId=c25e200e562d5, content=<a href='/topic/show?id=930139e38e' target=_blank style='color:#2F92EE;'>#CAF#</a>, objectTitle=Lancet Respir Med：Tezacaftor-iVacaftor治疗携带CFTR Phe508del突变的囊性纤维化患者的长期预后, objectType=article, longId=207122, objectId=8d1120e122ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d1120e122ef, replyNumber=0, likeNumber=85, createdTime=2022-01-02, rootId=0, userName=lvliquan, userId=796422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d1120e122ef, moduleTitle=Lancet Respir Med：Tezacaftor-iVacaftor治疗携带CFTR Phe508del突变的囊性纤维化患者的长期预后, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8d1120e122ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007561, encodeId=b733200e561d4, content=<a href='/topic/show?id=930139e38e' target=_blank style='color:#2F92EE;'>#CAF#</a>, objectTitle=FDA批准KALYDECO（ivacaftor）作为也是**的CFTR调节剂治疗囊性纤维化患儿, objectType=article, longId=201255, objectId=b45e20125596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b45e20125596, replyNumber=0, likeNumber=81, createdTime=2020-11-17, rootId=0, userName=lvliquan, userId=796422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b45e20125596, moduleTitle=FDA批准KALYDECO（ivacaftor）作为也是**的CFTR调节剂治疗囊性纤维化患儿, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b45e20125596)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007558, encodeId=8794200e5582b, content=<a href='/topic/show?id=930139e38e' target=_blank style='color:#2F92EE;'>#CAF#</a>, objectTitle=CAFS 2019：寻找突破口，探索心律失常药物治疗的崭新未来, objectType=article, longId=175494, objectId=6e9e1e5494f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e9e1e5494f8, replyNumber=0, likeNumber=68, createdTime=2020-02-02, rootId=0, userName=lvliquan, userId=796422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e9e1e5494f8, moduleTitle=CAFS 2019：寻找突破口，探索心律失常药物治疗的崭新未来, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6e9e1e5494f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007560, encodeId=b610200e56012, content=<a href='/topic/show?id=930139e38e' target=_blank style='color:#2F92EE;'>#CAF#</a>, objectTitle=NEJM：Elexacaftor-Tezacaftor-Ivacaftor治疗PHE508DEL型囊性纤维化, objectType=article, longId=182254, objectId=767318225483, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=767318225483, replyNumber=0, likeNumber=69, createdTime=2020-01-15, rootId=0, userName=lvliquan, userId=796422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=767318225483, moduleTitle=NEJM：Elexacaftor-Tezacaftor-Ivacaftor治疗PHE508DEL型囊性纤维化, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=767318225483)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007559, encodeId=0b9b200e55931, content=<a href='/topic/show?id=930139e38e' target=_blank style='color:#2F92EE;'>#CAF#</a>, objectTitle=欧洲CHMP持正面意见：KALYDECO（ivacaftor）治疗囊性纤维化婴儿, objectType=article, longId=181644, objectId=9c2d1816444b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c2d1816444b, replyNumber=0, likeNumber=70, createdTime=2020-06-05, rootId=0, userName=lvliquan, userId=796422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c2d1816444b, moduleTitle=欧洲CHMP持正面意见：KALYDECO（ivacaftor）治疗囊性纤维化婴儿, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9c2d1816444b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007554, encodeId=0875200e55412, content=<a href='/topic/show?id=930139e38e' target=_blank style='color:#2F92EE;'>#CAF#</a>, objectTitle=NEJM：VX-659-tezacaftor-ivacaftor三连疗法用于CFTR蛋白突变的囊性纤维化, objectType=article, longId=151869, objectId=2ac215186978, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ac215186978, replyNumber=0, likeNumber=107, createdTime=2019-04-18, rootId=0, userName=lvliquan, userId=796422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ac215186978, moduleTitle=NEJM：VX-659-tezacaftor-ivacaftor三连疗法用于CFTR蛋白突变的囊性纤维化, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2ac215186978)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007556, encodeId=600b200e556fb, content=<a href='/topic/show?id=930139e38e' target=_blank style='color:#2F92EE;'>#CAF#</a>, objectTitle=加拿大卫生部批准ORKAMBI（lumacaftor / ivacaftor）治疗儿童囊性纤维化, objectType=article, longId=155810, objectId=8a0115581040, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a0115581040, replyNumber=0, likeNumber=70, createdTime=2019-04-03, rootId=0, userName=lvliquan, userId=796422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a0115581040, moduleTitle=加拿大卫生部批准ORKAMBI（lumacaftor / ivacaftor）治疗儿童囊性纤维化, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8a0115581040)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007557, encodeId=50ca200e5578e, content=<a href='/topic/show?id=930139e38e' target=_blank style='color:#2F92EE;'>#CAF#</a>, objectTitle=加拿大卫生部授予KALYDECO（ivacaftor）治疗12个月至24个月囊性纤维化儿童的市场授权, objectType=article, longId=159164, objectId=c6ec15916468, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6ec15916468, replyNumber=0, likeNumber=104, createdTime=2019-11-09, rootId=0, userName=lvliquan, userId=796422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6ec15916468, moduleTitle=加拿大卫生部授予KALYDECO（ivacaftor）治疗12个月至24个月囊性纤维化儿童的市场授权, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c6ec15916468)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007555, encodeId=8338200e55563, content=<a href='/topic/show?id=930139e38e' target=_blank style='color:#2F92EE;'>#CAF#</a>, objectTitle=NEJM：VX-445-Tezacaftor-Ivacaftor用于治疗Phe508del突变型囊性纤维化, objectType=article, longId=151875, objectId=578e1518e5bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=578e1518e5bf, replyNumber=0, likeNumber=110, createdTime=2019-04-05, rootId=0, userName=lvliquan, userId=796422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=578e1518e5bf, moduleTitle=NEJM：VX-445-Tezacaftor-Ivacaftor用于治疗Phe508del突变型囊性纤维化, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=578e1518e5bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007553, encodeId=bfb2200e553d7, content=<a href='/topic/show?id=930139e38e' target=_blank style='color:#2F92EE;'>#CAF#</a>, objectTitle=J Clin Periodontol： CAF移植治疗上颌单个牙龈退缩的远期疗效, objectType=article, longId=148631, objectId=d2801486314d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2801486314d, replyNumber=0, likeNumber=121, createdTime=2019-06-10, rootId=0, userName=lvliquan, userId=796422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2801486314d, moduleTitle=J Clin Periodontol： CAF移植治疗上颌单个牙龈退缩的远期疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d2801486314d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007552, encodeId=5306200e552a2, content=<a href='/topic/show?id=930139e38e' target=_blank style='color:#2F92EE;'>#CAF#</a>, objectTitle=欧洲CHMP对SYMKEVI（tezacaftor / ivacaftor）持积极态度, objectType=article, longId=145412, objectId=a2591454128b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2591454128b, replyNumber=0, likeNumber=62, createdTime=2019-05-08, rootId=0, userName=lvliquan, userId=796422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2591454128b, moduleTitle=欧洲CHMP对SYMKEVI（tezacaftor / ivacaftor）持积极态度, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a2591454128b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007551, encodeId=1d1a200e55186, content=<a href='/topic/show?id=930139e38e' target=_blank style='color:#2F92EE;'>#CAF#</a>, objectTitle=Lancet respir med：lumacaftor与依法卡托联合治疗对6-11岁携带F508del-CFTR纯合突变的肺囊性纤维化患者的疗效如何？, objectType=article, longId=101423, objectId=a07f101423fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a07f101423fa, replyNumber=0, likeNumber=86, createdTime=2018-02-21, rootId=0, userName=lvliquan, userId=796422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a07f101423fa, moduleTitle=Lancet respir med：lumacaftor与依法卡托联合治疗对6-11岁携带F508del-CFTR纯合突变的肺囊性纤维化患者的疗效如何？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a07f101423fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007550, encodeId=317e200e5509b, content=<a href='/topic/show?id=930139e38e' target=_blank style='color:#2F92EE;'>#CAF#</a>, objectTitle=英国护士Pauline Cafferkey再次战胜埃博拉, objectType=article, longId=58813, objectId=cb9c5881310, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb9c5881310, replyNumber=0, likeNumber=77, createdTime=2015-12-25, rootId=0, userName=lvliquan, userId=796422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb9c5881310, moduleTitle=英国护士Pauline Cafferkey再次战胜埃博拉, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=cb9c5881310)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007549, encodeId=06f0200e5498e, content=<a href='/topic/show?id=930139e38e' target=_blank style='color:#2F92EE;'>#CAF#</a>, objectTitle=World J Surg Oncol：纤维腺瘤来源的乳腺癌（BcaFad）的研究, objectType=article, longId=42888, objectId=f52b4288863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f52b4288863, replyNumber=0, likeNumber=61, createdTime=2015-06-23, rootId=0, userName=lvliquan, userId=796422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f52b4288863, moduleTitle=World J Surg Oncol：纤维腺瘤来源的乳腺癌（BcaFad）的研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f52b4288863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007548, encodeId=3b1c200e548cf, content=<a href='/topic/show?id=930139e38e' target=_blank style='color:#2F92EE;'>#CAF#</a>, objectTitle=CAFS 2013：Ensite Velocity系统在持续性房颤的消融治疗中的应用, objectType=article, longId=22458, objectId=b8642245899, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8642245899, replyNumber=0, likeNumber=62, createdTime=2013-10-01, rootId=0, userName=lvliquan, userId=796422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8642245899, moduleTitle=CAFS 2013：Ensite Velocity系统在持续性房颤的消融治疗中的应用, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b8642245899)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

CAF

2020-05-29

lvliquan (审核中...)

前往app查看评论内容

#CAF#

Lancet Respir Med：Tezacaftor-iVacaftor治疗携带CFTR Phe508del突变的囊性纤维化患者的长期预后

2022-01-02

lvliquan (审核中...)

前往app查看评论内容

#CAF#

FDA批准KALYDECO（ivacaftor）作为也是**的CFTR调节剂治疗囊性纤维化患儿

2020-11-17

lvliquan (审核中...)

前往app查看评论内容

#CAF#

CAFS 2019：寻找突破口，探索心律失常药物治疗的崭新未来

2020-02-02

lvliquan (审核中...)

前往app查看评论内容

#CAF#

NEJM：Elexacaftor-Tezacaftor-Ivacaftor治疗PHE508DEL型囊性纤维化

2020-01-15

lvliquan (审核中...)

前往app查看评论内容

#CAF#

欧洲CHMP持正面意见：KALYDECO（ivacaftor）治疗囊性纤维化婴儿

2020-06-05

lvliquan (审核中...)

前往app查看评论内容

#CAF#

NEJM：VX-659-tezacaftor-ivacaftor三连疗法用于CFTR蛋白突变的囊性纤维化

2019-04-18

lvliquan (审核中...)

前往app查看评论内容

#CAF#

加拿大卫生部批准ORKAMBI（lumacaftor / ivacaftor）治疗儿童囊性纤维化

2019-04-03

lvliquan (审核中...)

前往app查看评论内容

#CAF#

加拿大卫生部授予KALYDECO（ivacaftor）治疗12个月至24个月囊性纤维化儿童的市场授权

2019-11-09

lvliquan (审核中...)

前往app查看评论内容

#CAF#

NEJM：VX-445-Tezacaftor-Ivacaftor用于治疗Phe508del突变型囊性纤维化

2019-04-05

lvliquan (审核中...)

前往app查看评论内容

#CAF#

J Clin Periodontol： CAF移植治疗上颌单个牙龈退缩的远期疗效

2019-06-10

lvliquan (审核中...)

前往app查看评论内容

#CAF#

欧洲CHMP对SYMKEVI（tezacaftor / ivacaftor）持积极态度

2019-05-08

lvliquan (审核中...)

前往app查看评论内容

#CAF#

Lancet respir med：lumacaftor与依法卡托联合治疗对6-11岁携带F508del-CFTR纯合突变的肺囊性纤维化患者的疗效如何？

2018-02-21

lvliquan (审核中...)

前往app查看评论内容

#CAF#

英国护士Pauline Cafferkey再次战胜埃博拉

2015-12-25

lvliquan (审核中...)

前往app查看评论内容

#CAF#

World J Surg Oncol：纤维腺瘤来源的乳腺癌（BcaFad）的研究

2015-06-23

lvliquan (审核中...)

前往app查看评论内容

#CAF#

CAFS 2013：Ensite Velocity系统在持续性房颤的消融治疗中的应用

2013-10-01

科室
- - 订阅+
  - 更多科室
工具
服务